Dan Massey

13.6k total citations · 2 hit papers
105 papers, 7.2k citations indexed

About

Dan Massey is a scholar working on Computer Networks and Communications, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dan Massey has authored 105 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Computer Networks and Communications, 43 papers in Pulmonary and Respiratory Medicine and 34 papers in Oncology. Recurrent topics in Dan Massey's work include Lung Cancer Treatments and Mutations (34 papers), Internet Traffic Analysis and Secure E-voting (21 papers) and IPv6, Mobility, Handover, Networks, Security (20 papers). Dan Massey is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Internet Traffic Analysis and Secure E-voting (21 papers) and IPv6, Mobility, Handover, Networks, Security (20 papers). Dan Massey collaborates with scholars based in United States, United Kingdom and China. Dan Massey's co-authors include Sarayut Lucien Geater, Nobuyuki Yamamoto, Vera Hirsh, Kenneth J. O’Byrne, Tony Mok, James Chih‐Hsin Yang, Martin Schüler, Lecia V. Sequist, Victoria Zazulina and Mehdi Shahidi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Dan Massey

100 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

2014 1.6k citations Yi‐Long Wu, Caicun Zhou et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Dan Massey

Since Specialization

Citations

This map shows the geographic impact of Dan Massey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Massey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Massey more than expected).

Fields of papers citing papers by Dan Massey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Massey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Massey. The network helps show where Dan Massey may publish in the future.

Co-authorship network of co-authors of Dan Massey

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Massey. A scholar is included among the top collaborators of Dan Massey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Massey. Dan Massey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease 2023 ·Breast Cancer Research ·Peter Schmid, Javier Cortés, Ana Joaquim, Noelia Martínez-Jáñez, Serafín Morales, (unknown), Sibel Blau, Patrick Neven, Julie Lemieux, José Á. García-Sáenz, Lowell L. Hart, Tsvetan Biyukov, (unknown), Dan Massey, Howard A. Burris, Hope S. Rugo	12
2	Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approach 2020 ·PLoS ONE ·Aashish R. Jha, Justin Shmalberg, (unknown), (unknown), Dan Massey, Ryan W. Honaker	36
3	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 2019 ·Journal of Cancer Research and Clinical Oncology ·Martin Schüler, Eng-Huat Tan, Kenneth J. O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih‐Hsin Yang, Ki Hyeong Lee, Shun Lü, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong‐Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Dan Massey, Angela Märten, Luis Paz‐Ares, Keunchil Park	31
4	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 2017 ·Patient ·Yi‐Long Wu, Vera Hirsh, Lecia V. Sequist, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Sarayut Lucien Geater, Caicun Zhou, Dan Massey, Angela Märten, Juliane Lungershausen, James Chih‐Hsin Yang	20
5	First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases 2016 ·QUT ePrints (Queensland University of Technology) ·Martin Schüler, Yi‐Long Wu, Vera Hirsh, Kenneth J. O’Byrne, Nobuyuki Yamamoto, Tony Mok, Sanjay Popat, Lecia V. Sequist, Dan Massey, Victoria Zazulina, James Chih‐Hsin Yang	1
6	P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6 2016 ·Journal of Thoracic Oncology ·Luis Fein, Yi‐Long Wu, Lecia V. Sequist, Sarayut Lucien Geater, Sergey Orlov, Ki Hyeong Lee, Chun‐Ming Tsai, Terufumi Kato, Katsuyuki Kiura, Carlos H. Barrios, Martin Schüler, Vera Hirsh, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Tony Mok, Dan Massey, Angela Märten, James Chih‐Hsin Yang	4
7	69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7 2016 ·Lung Cancer ·Kenneth J. O’Byrne, K. Park, (unknown), L. Zhang, Vera Hirsh, Michael Boyer, (unknown), Tony Mok, (unknown), Dan Massey, Victoria Zazulina, Luis Paz‐Ares	1
8	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 2016 ·British Journal of Cancer ·Yi‐Long Wu, Lecia V. Sequist, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wei Li, Mei Hou, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Neil Gibson, Dan Massey, Miyoung Kim, James Chih‐Hsin Yang	70
9	LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7) 2015 ·Annals of Oncology ·K. Park, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, (unknown), Tony Mok, (unknown), Dan Massey, Victoria Zazulina, Luis Paz‐Ares	12
10	446P Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) 2015 ·Annals of Oncology ·Yi‐Long Wu, Lecia V. Sequist, Sarayut Lucien Geater, Sergey Orlov, (unknown), C.-M. Tsai, Terufumi Kato, Katsuyuki Kiura, Carlos H. Barrios, Martin Schüler, Vera Hirsh, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Tony Mok, Dan Massey, Angela Märten, James Chih‐Hsin Yang	2
11	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma 2015 ·Lung Cancer ·Jacques De Grève, Teresa Morán, Marie-Pascale Graas, D. Galdermans, Peter Vuylsteke, Jean-Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey, Vikram K. Chand, Johan Vansteenkiste	69
12	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·Federico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, Paolo Bidoli, Adolfo Favaretto, Antonio Marchetti, Marialuisa Valente, A. Cseh, (unknown), Dan Massey, Armando Santoro	22
13	Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) 2014 ·European Respiratory Journal ·Martin Sebastian, James Chih‐Hsin Yang, Lecia V. Sequist, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Sarayut Lucien Geater, Caicun Zhou, Dan Massey, Victoria Zazulina, Yi‐Long Wu	6
14	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial breakdown → 2014 ·The Lancet Oncology ·Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater	1574
15	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations breakdown → 2013 ·Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2461
16	A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients 2010 ·Respiratory Medicine ·Eric Bateman, Donald P. Tashkin, Nikolaos M. Siafakas, Ronald Dahl, Lesley Towse, Dan Massey, D Pavia, Nanshan Zhong	89
17	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial 2010 ·The Lancet Neurology ·Paolo Barone, Werner Poewe, Stefan Albrecht, C. Debieuvre, Dan Massey, Olivier Rascol, Eduardo Tolosa, Daniel Weintraub	373
18	PHAS: a prefix hijack alert system 2006 ·USENIX Security Symposium ·Mohit Lad, Dan Massey, Dan Pei, (unknown), Beichuan Zhang, Lixia Zhang	159
19	Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997?2001 2006 ·International Journal of COPD ·M Pearson, Jon G. Ayres, Maria Sarno, Dan Massey, David Price	29
20	A TRIAL OF CONTINUOUS WINTER CHEMOTHERAPY IN CHRONIC BRONCHITIS 1960 ·The Lancet ·(unknown), (unknown), Dan Massey, (unknown), (unknown), Peter Stradling	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact